Potential IPF Therapy in Clinical Testing, MN-001, Cleared for Patent in Japan
A Japanese agency has cleared MediciNova’s request for a patent covering the use of its orally available candidates MN-001 (tipelukast) and MN-002 — a major metabolite of MN-001 — in treating idiopathic pulmonary fibrosis (IPF). The company announced it has received a Notice of Allowance from…